Peridialytic Hypotension | Predicting Hypotension During Dialysis in the ICU
Peridialytic Hypotension research study
What is the primary objective of this study?
Currently, decisions regarding volume management for dialysis sessions in the ICU are made in large part on the nephrologists'/intensivists' overall gestalt. This gestalt is based upon a combination of commonly used measures of circulatory function, the physical exam, fluid balance, estimates of dialysis dry weight, and monitoring changes in relative blood volume status using devices such as the Crit-Line™ III, and central venous pressures. However, these tools perform poorly in predicting the circulatory system's overall response to dialysis. Consequently, episodes of dangerously low blood pressure are still frequently encountered. Better techniques to predict the circulatory system's response to dialysis are much needed. The intent of this study is to test newer metrics of circulatory system function for their ability to predict low blood pressure episodes during dialysis. This is important because it may enable the design of newer treatment strategies created to prevent low blood pressure episodes during dialysis and improve patient outcomes. The investigators overall hypothesis is that newer measures of vascular volume and dynamic indices of fluid responsiveness, previously found to better reflect cardiac preload state than currently used parameters, will better predict low blood pressure episodes during dialysis than current methods.
Who is eligible to participate?
Inclusion Criteria: - Admitted to OHSU Hospitals ICUs - Patient has acute or chronic needs for intermittent hemodialysis support during their ICU stay for any reason other than isolated hyperkalemia - Central venous access in place separate from the dialysis catheter, or arteriovenous fistula or graft - Two or more organ systems affected by critical illness requiring supportive care as documented in the medical chart. Exclusion Criteria: - age younger than 18 years old - Weight > 160 kg - burns greater than 40% total body surface area - known cardiac or vascular aneurysm - contraindications to femoral arterial puncture - diagnosis of peripheral vascular disease - not committed to full support - participation in other experimental medication trial within 30 days - current atrial or ventricular arrhythmias - history of sever CHF- NYHA class >= III, previously documented EF < 30% - severe aortic regurgitation - anticipated ICU stay < 24 hrs - not expected to require dialysis > 48 hours
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Procedure:Transpulmonary ThermodilutionA PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
ICU Dialysis PatientsAny patient 18 years and older who is admitted to the OHSU Hospitals ICUs with ARF, or End Stage Renal Disease (ESRD) for a diagnosis other than hyperkalemia, as the sole determinant for that level of care, will be invited to participate. The patient must have acute or chronic needs for dialytic support during their ICU stay.
Start Date: July 19, 2010
Completed Date: March 11, 2013
Primary Outcome: hypotensive episode
Secondary Outcome: fluid removal tolerance
Study sponsors, principal investigator, and references
Principal Investigator: Charles R Phillips, MD
Lead Sponsor: Oregon Health and Science University
U.S. Renal Data System, USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2008.